gabapentin has been researched along with Abdominal Epilepsy in 87 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the effects of gabapentin monotherapy for people with epileptic focal seizures with and without secondary generalisation." | 9.41 | Gabapentin monotherapy for epilepsy: A review. ( Abakumova, T; Hoyle, CHV; Ziganshina, LE, 2023) |
| "To evaluate the comparative safety and adjunctive efficacy of pregabalin and gabapentin in reducing seizure frequency in patients with partial-onset seizures based on prestudy modeling showing superior efficacy for pregabalin." | 9.22 | Adjunctive pregabalin vs gabapentin for focal seizures: Interpretation of comparative outcomes. ( Almas, M; French, J; Friedman, D; Glue, P; Knapp, L; Pitman, V; Posner, HB; Yardi, N, 2016) |
| "To evaluate the long-term efficacy of gabapentin (GBP) and usefulness of measurement of the blood level for the observation of patients that have partial seizures." | 9.19 | The efficacy of gabapentin in children of partial seizures and the blood levels. ( Ishii, M; Iwasaki, T; Nonoda, Y, 2014) |
| "This randomised, double-blind study compared the newer antiepileptic drugs (AEDs) gabapentin (GBP) and lamotrigine (LTG) as monotherapy in newly diagnosed epilepsy." | 9.10 | Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. ( Anhut, H; Brodie, MJ; Chadwick, DW; Garofalo, EA; Maton, S; Messmer, SL; Murray, G; Otte, A; Sauermann, W, 2002) |
| "Studies in patients with epilepsy undergoing telemetry evaluation for surgery have suggested that discontinuation of carbamazepine (CBZ) is associated with increased seizures." | 9.09 | Increased seizures after discontinuing carbamazepine: results from the gabapentin monotherapy trial. ( DeToledo, JC; Garofalo, EA; Greiner, M; Lowe, MR; Ramsay, RE, 2000) |
| "Twenty-six children with intellectual disability and six normal children, all suffering from refractory partial seizures, received open-label gabapentin (range = 10-50 mg kg(-1) day(-1); mean = 26." | 9.08 | Gabapentin in the treatment of refractory partial epilepsy in children with intellectual disability. ( Choueri, R; Helmers, S; Holmes, G; Khurana, DS; Mikati, MA; Riviello, J, 1998) |
| "Gabapentin is widely approved as add-on therapy for epilepsy treatment for partial seizures with and without secondary generalization." | 9.08 | A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77. ( Alexander, J; Anhut, H; Chadwick, DW; Garofalo, EA; Greiner, MJ; Murray, GH; Pierce, MW, 1998) |
| "Gabapentin's potential role in the treatment of epilepsy also was assessed." | 6.39 | Gabapentin: a new agent for the management of epilepsy. ( Andrews, CO; Fischer, JH, 1994) |
| "Gabapentin is an antiepileptic drug approved for adjunctive therapy for partial seizures." | 5.42 | THROMBOCYTOPENIA WITH GABAPENTIN USAGE. ( Ak, PD; Atakli, D; Sari, H; Sariahmetoglu, H; Yuksel, B, 2015) |
| "To assess the effects of gabapentin monotherapy for people with epileptic focal seizures with and without secondary generalisation." | 5.41 | Gabapentin monotherapy for epilepsy: A review. ( Abakumova, T; Hoyle, CHV; Ziganshina, LE, 2023) |
| "To evaluate the comparative safety and adjunctive efficacy of pregabalin and gabapentin in reducing seizure frequency in patients with partial-onset seizures based on prestudy modeling showing superior efficacy for pregabalin." | 5.22 | Adjunctive pregabalin vs gabapentin for focal seizures: Interpretation of comparative outcomes. ( Almas, M; French, J; Friedman, D; Glue, P; Knapp, L; Pitman, V; Posner, HB; Yardi, N, 2016) |
| "To evaluate the long-term efficacy of gabapentin (GBP) and usefulness of measurement of the blood level for the observation of patients that have partial seizures." | 5.19 | The efficacy of gabapentin in children of partial seizures and the blood levels. ( Ishii, M; Iwasaki, T; Nonoda, Y, 2014) |
| "This randomised, double-blind study compared the newer antiepileptic drugs (AEDs) gabapentin (GBP) and lamotrigine (LTG) as monotherapy in newly diagnosed epilepsy." | 5.10 | Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. ( Anhut, H; Brodie, MJ; Chadwick, DW; Garofalo, EA; Maton, S; Messmer, SL; Murray, G; Otte, A; Sauermann, W, 2002) |
| "Studies in patients with epilepsy undergoing telemetry evaluation for surgery have suggested that discontinuation of carbamazepine (CBZ) is associated with increased seizures." | 5.09 | Increased seizures after discontinuing carbamazepine: results from the gabapentin monotherapy trial. ( DeToledo, JC; Garofalo, EA; Greiner, M; Lowe, MR; Ramsay, RE, 2000) |
| "Twenty-six children with intellectual disability and six normal children, all suffering from refractory partial seizures, received open-label gabapentin (range = 10-50 mg kg(-1) day(-1); mean = 26." | 5.08 | Gabapentin in the treatment of refractory partial epilepsy in children with intellectual disability. ( Choueri, R; Helmers, S; Holmes, G; Khurana, DS; Mikati, MA; Riviello, J, 1998) |
| "Gabapentin is widely approved as add-on therapy for epilepsy treatment for partial seizures with and without secondary generalization." | 5.08 | A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77. ( Alexander, J; Anhut, H; Chadwick, DW; Garofalo, EA; Greiner, MJ; Murray, GH; Pierce, MW, 1998) |
| "Fifty patients with refractory partial seizures took part in a prospective, observational study of adjuvant gabapentin (GBP) in increasing doses." | 5.08 | High dose gabapentin in refractory partial epilepsy: clinical observations in 50 patients. ( Brodie, MJ; Forrest, G; Sills, GJ; Wilson, EA, 1998) |
| "Gabapentin is a new antiepileptic drug for add-on therapy in patients above the age of 12 years with otherwise refractory partial seizures." | 3.78 | [Gabapentin (Neurontin): a new possibility in the add-on therapy of partial epilepsies]. ( Krämer, G, 1996) |
| " The second patient complained of impotence after a rash while taking phenytoin and carbamazepine." | 3.70 | Improved sexual function in three men taking lamotrigine for epilepsy. ( Carwile, ST; Husain, AM; Miller, PP; Radtke, RA, 2000) |
| " We estimated summary risk ratios (RR) for each outcome and evaluated dose-response in regression models." | 2.72 | Gabapentin add-on treatment for drug-resistant focal epilepsy. ( Al-Bachari, S; Hutton, JL; Marson, AG; Panebianco, M, 2021) |
| "005) with definite dose-response (P < 0." | 2.72 | Treatment of partial seizures with gabapentin: double-blind, placebo-controlled, parallel-group study. ( Kaneko, S; Sase, S; Yagi, K; Yamauchi, T, 2006) |
| " Patients randomized to GBP started on 1800 mg/d and could have their dosage increased stepwise to 2400 and 3600 mg/d if seizures persisted." | 2.71 | Serum concentrations and effects of gabapentin and vigabatrin: observations from a dose titration study. ( Johannessen, SI; Larsson, S; Lindberger, M; Luhr, O; Tomson, T, 2003) |
| "Starting gabapentin therapy at an initial therapeutic dosage of 900 mg/day is well tolerated by patients with epilepsy and is as safe as initiating with a titration schedule over 3 days." | 2.70 | Rapid initiation of gabapentin: a randomized, controlled trial. ( Bernstein, P; Fisher, RS; Magnus, L; Pellock, J; Penovich, PE; Sachdeo, RC, 2001) |
| "All patients had medically refractory focal epilepsy and received other antiepileptic drugs (AEDs) besides the study medication." | 2.70 | Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin. ( Feuerstein, TJ; Huppertz, HJ; Schulze-Bonhage, A, 2001) |
| " Weight gain, somnolence, nystagmus, and dizziness were the major adverse events in these patients, whereas ataxia, tremor, and diplopia were found with gabapentin in a dose higher than 1,800 mg/day." | 2.70 | Efficacy and safety of gabapentin as an add-on therapy in refractory partial epileptic patients. ( Rungreangyingyod, L; Suthisisang, C; Towanabut, S, 2001) |
| "Gabapentin mean dose was 2117." | 2.69 | Conversion from thrice daily to twice daily administration of gabapentin (GBP) in partial epilepsy: analysis of clinical efficacy and plasma levels. ( Arnetoli, G; Balestrieri, F; Chiroli, S; Luceri, F; Mastio, MD; Muscas, GC, 2000) |
| "Gabapentin was titrated up to a maximal dosage of 3600 mg/day to achieve seizure control or to tolerability." | 2.69 | Dosing to efficacy with neurontin: the STEPS trial. Study of Titration to Effect Profile of Safety. ( Morrell, MJ, 1999) |
| "Gabapentin was started at 400 mg/day and was individually titrated to effective tolerable dose up to 2400 mg/day." | 2.69 | Outcome evaluation of gabapentin as add-on therapy for partial seizures. "NEON" Study Investigators Group. Neurontin Evaluation of Outcomes in Neurological Practice. ( Bruni, J, 1998) |
| "Forty adult patients with partial epilepsy were studied in a prospective, non-randomized fashion with interviewer-rated and self-rated scales of mood and anxiety: the Cornell Dysthymia Rating Scale (CDRS), Beck Depression Inventory (BDI), and Hamilton Depression (Ham-D) and Anxiety (Ham-A) Scales." | 2.69 | A beneficial effect on mood in partial epilepsy patients treated with gabapentin. ( Carson, D; Goldstein, MA; Harden, CL; Kocsis, JH; Labar, DR; Lazar, LM; Nikolov, B; Pick, LH; Ravdin, LD, 1999) |
| "The gabapentin dosage was titrated to effective tolerated dose up to 2400 mg/day." | 2.69 | Gabapentin as adjunctive therapy for partial seizures. ( Bruni, J, 1999) |
| " A significant linear correlation between daily GBP dosage (2,400-4,800 mg) and resultant mean serum levels was found (r = 0." | 2.69 | Conversion to high dose gabapentin monotherapy in patients with medically refractory partial epilepsy. ( Abou-Khalil, B; Beydoun, A; Fakhoury, T; Nasreddine, W, 1998) |
| "Gabapentin was well tolerated at all doses in this study." | 2.69 | Efficacy of gabapentin as adjunctive therapy in a large, multicenter study. The Steps Study Group. ( Bernstein, P; Faught, RE; Holmes, GL; Magnus, L; McLean, MJ; Morrell, MJ; Privitera, MD; Willmore, LJ, 2000) |
| "Gabapentin is a new antiepileptic for the combination therapy of partial seizures." | 2.68 | [Clinical studies on gabapentin in Switzerland]. ( Shokry, A, 1996) |
| "Gabapentin is an analogue of gamma aminobutyric acid (GABA) which has anticonvulsant properties in animals." | 2.67 | Gabapentin in partial epilepsy. UK Gabapentin Study Group. ( , 1990) |
| " At the time of data cutoff, 30% of patients had withdrawn from the study due to lack of efficacy, and 4% due to adverse events." | 2.67 | The long-term safety and efficacy of gabapentin (Neurontin) as add-on therapy in drug-resistant partial epilepsy. The US Gabapentin Study Group. ( , 1994) |
| "Gabapentin (GBP) is a neutral amino acid and a GABA analog which in animal experimental models has shown a broad anticonvulsant spectrum." | 2.67 | Selected CSF biochemistry and gabapentin concentrations in the CSF and plasma in patients with partial seizures after a single oral dose of gabapentin. ( Ben-Menachem, E; Hedner, T; Persson, LI, 1992) |
| "Gabapentin was studied as an open-label 'add-on' antiepileptic drug in 35 patients with partial seizures." | 2.67 | Long-term treatment with gabapentin for partial epilepsy. ( Chmelir, T; Ojemann, LM; Ricker, BA; Temkin, NR; Wallace, J; Wilensky, AJ, 1992) |
| "28), indicating a dose-response relationship." | 2.61 | Pregabalin add-on for drug-resistant focal epilepsy. ( Bresnahan, R; Hemming, K; Marson, AG; Panebianco, M, 2019) |
| " We estimated summary risk ratios (RR) for each outcome and evaluated dose-response in regression models." | 2.58 | Gabapentin add-on treatment for drug-resistant focal epilepsy. ( Al-Bachari, S; Hutton, JL; Marson, AG; Panebianco, M; Weston, J, 2018) |
| "Epilepsy is a common neurological condition with a worldwide prevalence of around 1%." | 2.55 | Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. ( Marson, AG; Nevitt, SJ; Sudell, M; Tudur Smith, C; Weston, J, 2017) |
| "Epilepsy is a common neurological condition with a worldwide prevalence of around 1%." | 2.55 | Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. ( Marson, AG; Nevitt, SJ; Sudell, M; Tudur Smith, C; Weston, J, 2017) |
| " We estimated summary risk ratios for each outcome and evaluated dose-response in regression models." | 2.49 | Gabapentin add-on for drug-resistant partial epilepsy. ( Al-Bachari, S; Hutton, JL; Marson, AG; Pulman, J, 2013) |
| "In patients with refractory partial epilepsy, pregabalin is likely to be more effective than gabapentin at comparable effective doses, based on clinical response and the number of SFD." | 2.46 | Pregabalin versus gabapentin in partial epilepsy: a meta-analysis of dose-response relationships. ( Delahoy, P; Marschner, IC; Thompson, S, 2010) |
| "Gabapentin has efficacy as an add-on treatment in patients with drug-resistant partial epilepsy." | 2.41 | Gabapentin for drug-resistant partial epilepsy. ( Chadwick, DW; Hutton, JL; Kadir, ZA; Marson, AG, 2000) |
| "Gabapentin has efficacy as an add-on treatment in patients with drug-resistant partial epilepsy." | 2.41 | Gabapentin add-on for drug-resistant partial epilepsy. ( Chadwick, DW; Hutton, JL; Kadir, ZA; Marson, AG, 2000) |
| "Gabapentin has few drug-drug interactions, none of which is clinically limiting." | 2.40 | Gabapentin in the management of convulsive disorders. ( McLean, MJ, 1999) |
| " GBP is also active in this population, but only the 1,800 mg/day dosage was significantly better than placebo with respect to percent responders." | 2.39 | Clinical efficacy of new antiepileptic drugs in refractory partial epilepsy: experience in the United States with three novel drugs. ( French, JA, 1996) |
| "Gabapentin's potential role in the treatment of epilepsy also was assessed." | 2.39 | Gabapentin: a new agent for the management of epilepsy. ( Andrews, CO; Fischer, JH, 1994) |
| "Gabapentin, has shown significant promise in the treatment of patients with refractory partial seizures and secondarily generalized tonic-clonic seizures." | 2.39 | Clinical efficacy and safety of gabapentin. ( Ramsay, RE, 1994) |
| "Gabapentin is an antiepileptic drug approved for adjunctive therapy for partial seizures." | 1.42 | THROMBOCYTOPENIA WITH GABAPENTIN USAGE. ( Ak, PD; Atakli, D; Sari, H; Sariahmetoglu, H; Yuksel, B, 2015) |
| " A substantially lower median seizure frequency was observed at all gabapentin dosing periods (visit I - 2." | 1.37 | [Efficacy and tolerability of dose-escalation with generic gabapentin--a multicenter, non-interventional study]. ( Kaczyński, K; Lipa, A; Rejdak, K; Stelmasiak, Z, 2011) |
| "Lamotrigine is a useful add-on therapy in treating children with epilepsy." | 1.33 | The use of lamotrigine, vigabatrin and gabapentin as add-on therapy in intractable epilepsy of childhood. ( Keegan, MB; Madden, D; McDonald, DG; McMenamin, JB; Najam, Y; Whooley, M, 2005) |
| "Gabapentin (GBP) is a commonly used drug in the treatment of partial seizures, but its mode of action is still unclear." | 1.32 | Gabapentin increases the hyperpolarization-activated cation current Ih in rat CA1 pyramidal cells. ( Feuerstein, TJ; Freiman, TM; Surges, R, 2003) |
| " The most frequent adverse events were dizziness (31%), fatigue (29%), somnolence (27%), headache (21%), and ataxia (20%), with no major increase seen in adverse events necessitating discontinuation as the dose of GBP was titrated upward." | 1.31 | AUStralian study of titration to effect profile of safety (AUS-STEPS): high-dose gabapentin (neurontin) in partial seizures. ( Beran, R; Berkovic, S; Black, A; Danta, G; Dunne, J; Frasca, J; Grainger, K; Kilpatrick, C; McKenzie, R; McLaughlin, D; Schapel, G; Somerville, E, 2001) |
| "Gabapentin has been accepted worldwide as a novel antiepileptic drug with a favourable tolerability profile." | 1.30 | Isolated ataxia as an idiosyncratic side-effect under gabapentin. ( Bittermann, HJ; Herrendorf, G; Kurth, C; Steinhoff, BJ, 1997) |
| " A 6-month multicentre, open-label study, involved addition of gabapentin to pre-existing treatment at the initial dosage of 1200 mg and subsequent adjustment between 900 and 2400 mg/day according to efficacy and tolerability." | 1.30 | Gabapentin add-on therapy with adaptable dosages in 610 patients with partial epilepsy: an open, observational study. The French Gabapentin Collaborative Group. ( Arzimanoglou, A; Baulac, M; Cavalcanti, D; Portal, JJ; Semah, F, 1998) |
| "Gabapentin is an antiepileptic agent that is indicated for use as adjunctive therapy for partial seizures." | 1.30 | A case of sustained massive gabapentin overdose without serious side effects. ( Radtke, RA; St Clair, EW; Verma, A, 1999) |
| "Thirty-two children with refractory partial epilepsy received open-label gabapentin as an additional medication to their antiepileptic drug regimen." | 1.29 | Efficacy of gabapentin therapy in children with refractory partial seizures. ( Anderson, J; Helmers, S; Holmes, G; Khurana, DS; Mikati, MA; Riviello, J, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 39 (44.83) | 18.2507 |
| 2000's | 32 (36.78) | 29.6817 |
| 2010's | 14 (16.09) | 24.3611 |
| 2020's | 2 (2.30) | 2.80 |
| Authors | Studies |
|---|---|
| Ziganshina, LE | 1 |
| Abakumova, T | 1 |
| Hoyle, CHV | 1 |
| Panebianco, M | 3 |
| Al-Bachari, S | 3 |
| Hutton, JL | 5 |
| Marson, AG | 9 |
| Nevitt, SJ | 2 |
| Sudell, M | 2 |
| Weston, J | 3 |
| Tudur Smith, C | 2 |
| Bresnahan, R | 1 |
| Hemming, K | 1 |
| Nonoda, Y | 1 |
| Iwasaki, T | 1 |
| Ishii, M | 1 |
| Pulman, J | 1 |
| Atakli, D | 1 |
| Yuksel, B | 1 |
| Ak, PD | 1 |
| Sariahmetoglu, H | 1 |
| Sari, H | 1 |
| French, J | 1 |
| Glue, P | 1 |
| Friedman, D | 1 |
| Almas, M | 1 |
| Yardi, N | 1 |
| Knapp, L | 1 |
| Pitman, V | 1 |
| Posner, HB | 1 |
| Rouvel-Tallec, A | 1 |
| Delahoy, P | 1 |
| Thompson, S | 1 |
| Marschner, IC | 1 |
| Costa, J | 1 |
| Fareleira, F | 1 |
| Ascenção, R | 1 |
| Borges, M | 1 |
| Sampaio, C | 1 |
| Vaz-Carneiro, A | 1 |
| Rejdak, K | 1 |
| Lipa, A | 1 |
| Kaczyński, K | 1 |
| Stelmasiak, Z | 1 |
| Faught, E | 1 |
| Bonnett, L | 1 |
| Smith, CT | 1 |
| Smith, D | 1 |
| Williamson, P | 1 |
| Chadwick, D | 2 |
| Kleinman, NL | 1 |
| Sadosky, A | 1 |
| Seid, J | 1 |
| Martin, RC | 1 |
| Labiner, DM | 1 |
| van Rijckevorsel, K | 1 |
| Boon, PA | 1 |
| Brodie, MJ | 4 |
| Chadwick, DW | 4 |
| Anhut, H | 2 |
| Otte, A | 1 |
| Messmer, SL | 1 |
| Maton, S | 1 |
| Sauermann, W | 1 |
| Murray, G | 2 |
| Garofalo, EA | 3 |
| Sethi, A | 1 |
| Chandra, D | 1 |
| Puri, V | 1 |
| Mallika, V | 1 |
| Surges, R | 1 |
| Freiman, TM | 1 |
| Feuerstein, TJ | 2 |
| Lindberger, M | 2 |
| Luhr, O | 1 |
| Johannessen, SI | 2 |
| Larsson, S | 2 |
| Tomson, T | 2 |
| French, JA | 4 |
| Kanner, AM | 3 |
| Bautista, J | 3 |
| Abou-Khalil, B | 4 |
| Browne, T | 3 |
| Harden, CL | 4 |
| Theodore, WH | 3 |
| Bazil, C | 3 |
| Stern, J | 3 |
| Schachter, SC | 3 |
| Bergen, D | 3 |
| Hirtz, D | 3 |
| Montouris, GD | 3 |
| Nespeca, M | 3 |
| Gidal, B | 3 |
| Marks, WJ | 3 |
| Turk, WR | 3 |
| Fischer, JH | 4 |
| Bourgeois, B | 3 |
| Wilner, A | 3 |
| Faught, RE | 4 |
| Sachdeo, RC | 4 |
| Beydoun, A | 5 |
| Glauser, TA | 3 |
| McDonald, DG | 1 |
| Najam, Y | 1 |
| Keegan, MB | 1 |
| Whooley, M | 1 |
| Madden, D | 1 |
| McMenamin, JB | 1 |
| Verdru, P | 1 |
| Yamauchi, T | 1 |
| Kaneko, S | 1 |
| Yagi, K | 1 |
| Sase, S | 2 |
| Taylor, CP | 1 |
| Angelotti, T | 1 |
| Fauman, E | 1 |
| Kunihara, M | 1 |
| Arakawa, A | 1 |
| Macleod, S | 1 |
| Appleton, RE | 1 |
| Ryback, R | 1 |
| Ryback, L | 1 |
| Devinsky, O | 1 |
| Vazquez, B | 1 |
| Luciano, D | 1 |
| Andrews, CO | 1 |
| Ramsay, RE | 2 |
| Leiderman, DB | 1 |
| Fromm, GH | 1 |
| Krämer, G | 1 |
| Shokry, A | 2 |
| Buetefisch, CM | 1 |
| Gutierrez, A | 1 |
| Gutmann, L | 1 |
| Khurana, DS | 2 |
| Riviello, J | 2 |
| Helmers, S | 2 |
| Holmes, G | 2 |
| Anderson, J | 1 |
| Mikati, MA | 2 |
| Hughes, D | 1 |
| Cockerell, OC | 1 |
| Bannister, SM | 1 |
| Morton, LD | 1 |
| Pellock, JM | 1 |
| Leach, JP | 1 |
| Girvan, J | 1 |
| Paul, A | 1 |
| Picard, C | 1 |
| Jonville-Bera, AP | 1 |
| Billard, C | 1 |
| Autret, E | 1 |
| Pierce, MW | 2 |
| Wilson, EA | 1 |
| Sills, GJ | 1 |
| Forrest, G | 1 |
| Steinhoff, BJ | 1 |
| Herrendorf, G | 1 |
| Bittermann, HJ | 1 |
| Kurth, C | 1 |
| Baulac, M | 1 |
| Cavalcanti, D | 1 |
| Semah, F | 1 |
| Arzimanoglou, A | 1 |
| Portal, JJ | 1 |
| Fakhoury, T | 1 |
| Nasreddine, W | 1 |
| Elger, CE | 1 |
| Bauer, J | 1 |
| Scherrmann, J | 1 |
| Widman, G | 1 |
| Bruni, J | 2 |
| Greiner, MJ | 1 |
| Alexander, J | 2 |
| Murray, GH | 1 |
| Choueri, R | 1 |
| Lazar, LM | 1 |
| Pick, LH | 1 |
| Nikolov, B | 1 |
| Goldstein, MA | 1 |
| Carson, D | 1 |
| Ravdin, LD | 1 |
| Kocsis, JH | 1 |
| Labar, DR | 1 |
| Appleton, R | 1 |
| Fichtner, K | 1 |
| LaMoreaux, L | 1 |
| Halsall, G | 1 |
| Garofalo, E | 1 |
| Morrell, MJ | 2 |
| McLean, MJ | 2 |
| Privitera, MD | 2 |
| Verma, A | 1 |
| St Clair, EW | 1 |
| Radtke, RA | 2 |
| Muscas, GC | 1 |
| Chiroli, S | 1 |
| Luceri, F | 1 |
| Mastio, MD | 1 |
| Balestrieri, F | 1 |
| Arnetoli, G | 1 |
| Mattia, D | 1 |
| Spanedda, F | 1 |
| Bassetti, MA | 1 |
| Romigi, A | 1 |
| Placidi, F | 1 |
| Marciani, MG | 1 |
| Husain, AM | 1 |
| Carwile, ST | 1 |
| Miller, PP | 1 |
| Kadir, ZA | 2 |
| Willmore, LJ | 1 |
| Holmes, GL | 1 |
| Magnus, L | 2 |
| Bernstein, P | 2 |
| Bourgeois, BF | 1 |
| Trinka, E | 1 |
| Niedermüller, U | 1 |
| Thaler, C | 1 |
| Doering, S | 1 |
| Moroder, T | 1 |
| Ladurner, G | 1 |
| Bauer, G | 1 |
| Alenius, M | 1 |
| Frisén, L | 1 |
| Malmgren, K | 1 |
| DeToledo, JC | 1 |
| Lowe, MR | 1 |
| Greiner, M | 1 |
| Fisher, RS | 1 |
| Pellock, J | 1 |
| Penovich, PE | 1 |
| Huppertz, HJ | 1 |
| Schulze-Bonhage, A | 1 |
| Gaida-Hommernick, B | 1 |
| Rieck, K | 1 |
| Runge, U | 1 |
| Towanabut, S | 1 |
| Rungreangyingyod, L | 1 |
| Suthisisang, C | 1 |
| Beran, R | 1 |
| Berkovic, S | 1 |
| Black, A | 1 |
| Danta, G | 1 |
| Dunne, J | 1 |
| Frasca, J | 1 |
| Grainger, K | 1 |
| Kilpatrick, C | 1 |
| McKenzie, R | 1 |
| McLaughlin, D | 1 |
| Schapel, G | 1 |
| Somerville, E | 1 |
| Ben-Menachem, E | 1 |
| Persson, LI | 1 |
| Hedner, T | 1 |
| Ojemann, LM | 1 |
| Wilensky, AJ | 1 |
| Temkin, NR | 1 |
| Chmelir, T | 1 |
| Ricker, BA | 1 |
| Wallace, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Parallel-group Multi-center Comparative Flexible-dose Trial Of Pregabalin Versus Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures.[NCT00537940] | Phase 4 | 482 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Multicentre, Double-blind, Randomized, Phase IV Clinical Trial Comparing the Safety, Tolerability and Efficacy of Levetiracetam Versus Lamotrigine and Carbamazepine in the Oral Antiepileptic Therapy of Newly Diagnosed Elderly Patients With Focal Epileps[NCT00438451] | Phase 4 | 361 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Phase 3: Metabolism of Lamotrigine During Treatment With Oral Contraceptives[NCT00266149] | Phase 3 | 10 participants | Interventional | 2003-06-30 | Terminated | ||
| Exploratory Study on the Use of Pregabalin for the Treatment of Taxol Related Arthralgia-Myalgia[NCT02024568] | Phase 2 | 38 participants (Anticipated) | Interventional | 2013-12-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The seizures were recorded by the participants, by a family member, by a caregiver, or by a legal guardian and documented in a daily seizure diary. Participant's 28-day seizure frequency of all partial seizure was assessed during double blind (TP + MP) phase compared with baseline. Total partial seizure is defined as the total number of (simple partial seizure + complex partial seizure + secondary generalized tonic clonic seizure [SGTC]). (NCT00537940)
Timeframe: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks
| Intervention | percent change (Median) |
|---|---|
| Pregabalin | -58.65 |
| Gabapentin | -57.43 |
SGTC Responder is defined as a participant who shows reduction from Baseline to double-blind phase in proportion of 28-Day SGTC Seizure Rate to 28-Day All Partial Seizure Rate. (NCT00537940)
Timeframe: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks
| Intervention | percentage of responders (Number) |
|---|---|
| Pregabalin | 30.8 |
| Gabapentin | 39.8 |
Change in SGTC = (Proportion of SGTC/All Partial Seizure rate during at the double-blind phase) - (Proportion of SGTC/All Partial Seizure rate at Baseline). Negative values indicate reduction from baseline. (NCT00537940)
Timeframe: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks
| Intervention | percentage of all partial seizure/28days (Mean) | |
|---|---|---|
| Baseline (n=114, 114) | Change from Baseline at Double Blind (n=104, 98) | |
| Gabapentin | 59.60 | -2.17 |
| Pregabalin | 56.53 | 1.59 |
HADS: participant rated questionnaire with 2 subscales. Hospital Anxiety and Depression Scale - anxiety (HADS-A) assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); Hospital Anxiety and Depression Scale - depression (HADS-D) assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms. (NCT00537940)
Timeframe: Baseline, Week 21
| Intervention | Units on a scale (Least Squares Mean) | |||
|---|---|---|---|---|
| Baseline HADS-A (n=238, 240) | HADS- A Change at Week 21/ET (n=212, 210) | Baseline HADS-D (n=238, 240) | HADS-D Change at Week 21/ET (n=212, 210) | |
| Gabapentin | 7.60 | -0.83 | 5.65 | -0.42 |
| Pregabalin | 7.82 | -0.92 | 5.94 | -0.59 |
Participant-rated 12-item questionnaire to assess constructs of sleep over past week; 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity (range:0-24), optimal sleep (yes/no), and 9 item index measures of sleep disturbance provide composite scores: sleep problem summary, overall sleep problem. Except adequacy, optimal sleep and quantity, higher scores=more impairment. Scores transformed (actual raw score [RS] minus lowest possible score divided by possible RS range*100); total score range:0-100; higher score=more intensity of attribute. (NCT00537940)
Timeframe: Baseline, Week 21
| Intervention | Units on a scale (Least Squares Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: Sleep Disturbance (n=238, 240) | Baseline: Snoring (n=238, 240) | Baseline: Awaken Short of Breath (n=238, 240) | Baseline: Quantity of Sleep (n=238, 240) | Baseline: Adequacy of Sleep (n=238, 240) | Baseline: Somnolence (n=238, 240) | Baseline: Sleep Problem Index (9) (n=238, 240) | Week 21: Sleep Disturbance (n=212, 210) | Week 21: Snoring (n=212, 210) | Week 21: Awaken Short of Breath (n=212, 210) | Week 21: Quantity of Sleep (n=212, 210) | Week 21: Adequacy of Sleep (n=212, 210) | Week 21: Somnolence (n=212, 210) | Week 21: Sleep Problem Index (9) (n=212, 210) | |
| Gabapentin | 26.43 | 28.09 | 19.61 | 7.59 | 63.67 | 29.31 | 28.15 | 25.31 | 26.12 | 18.20 | 8.77 | 64.53 | 29.98 | 27.54 |
| Pregabalin | 29.68 | 29.28 | 23.64 | 7.56 | 61.30 | 32.29 | 31.60 | 24.99 | 28.07 | 16.26 | 8.79 | 63.87 | 32.04 | 27.88 |
Participants who had at least 50% reduction in seizure frequency from Baseline to double-blind treatment (TP + MP) were considered as 50% responders. If percent change from baseline <= -50 then responder rate = 1 (yes) otherwise responder rate = 0 (no). (NCT00537940)
Timeframe: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| All Partial Seizure (n=238, 240) | Simple Partial (n=87, 88) | Complex Partial (n=161, 158) | SGTC (n=112, 114) | |
| Gabapentin | 58.3 | 53.4 | 55.1 | 60.5 |
| Pregabalin | 56.3 | 55.2 | 56.5 | 50.9 |
Participants who had at least 75% reduction in seizure frequency from Baseline to double-blind treatment (TP + MP) were considered as 75% responders. If percent change from baseline <= -75 then 75% responder rate = 1 (yes) otherwise responder rate = 0 (no). Total partial seizure is defined as the total number of (simple partial seizure + complex partial seizure + SGTC). (NCT00537940)
Timeframe: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| All Partial Seizure (n=238, 240) | Simple Partial (n=87, 88) | Complex Partial (n=161, 158) | SGTC (n=112, 114) | |
| Gabapentin | 34.2 | 33.0 | 36.1 | 43.9 |
| Pregabalin | 33.6 | 36.8 | 37.3 | 38.4 |
MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Percentage of participants with optimal sleep are reported. (NCT00537940)
Timeframe: Baseline, Week 21
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Baseline (n=238, 240) | Week 21 (n=212, 210) | |
| Gabapentin | 58.8 | 58.6 |
| Pregabalin | 49.2 | 51.4 |
Seizure free for 28 days was defined as participants who have not experienced any seizure (simple partial, complex partial and SGTC) for at least 28 consecutive days from their last seizure until the end of the MP. Same participant could be seizure free for a specific type of seizure but not necessarily for the other types of seizure. (NCT00537940)
Timeframe: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| All Partial Seizure (n=189, 182) | Simple Partial (n=74, 66) | Complex Partial (n=126, 123) | SGTC (n=95, 91) | |
| Gabapentin | 34.1 | 36.4 | 40.7 | 42.9 |
| Pregabalin | 30.7 | 29.7 | 37.3 | 46.3 |
(NCT00438451)
Timeframe: 58 weeks
| Intervention | proportion of participants (Mean) |
|---|---|
| Levetiracetam | 0.61 |
| Carbamazepine | 0.46 |
| Lamotrigine | 0.56 |
Percentage of patients experiencing no seizures until week 58 (Visit 6) and did not discontinue the study until week 58. (NCT00438451)
Timeframe: week 58
| Intervention | percentage of participants (Number) |
|---|---|
| Levetiracetam | 43 |
| Carbamazepine | 33 |
| Lamotrigine | 38 |
Percentage of patients experiencing no seizures until week 30 (Visit 4) and did not discontinue the study until week 30. (NCT00438451)
Timeframe: Week 30
| Intervention | percentage of participants (Number) |
|---|---|
| Levetiracetam | 48 |
| Carbamazepine | 39 |
| Lamotrigine | 49 |
(NCT00438451)
Timeframe: 52 weeks
| Intervention | proportion of seizure-free days (Number) |
|---|---|
| Levetiracetam | 0.99 |
| Carbamazepine | 0.99 |
| Lamotrigine | 0.99 |
EPITrack-Score shows the performance of attention and executive functions. Higher values indicate a better performance. The results of EPITrack Score ranges between 7 and 45. (NCT00438451)
Timeframe: week 58
| Intervention | units on a scale (Mean) |
|---|---|
| Levetiracetam | 26.0 |
| Carbamazepine | 26.0 |
| Lamotrigine | 25.4 |
"Seizure frequency was assessed by investigators in the CRF at the Visits V3, V4, V5 and V6.~The absolute seizure frequency during the maintenance phase was defined as the sum of those entries." (NCT00438451)
Timeframe: over 52 weeks
| Intervention | number of seizures (Number) |
|---|---|
| Levetiracetam | 168 |
| Carbamazepine | 131 |
| Lamotrigine | 130 |
(NCT00438451)
Timeframe: over the whole duration of 58 weeks
| Intervention | days (Median) |
|---|---|
| Levetiracetam | NA |
| Carbamazepine | NA |
| Lamotrigine | NA |
number of days between randomization and premature discontinuation of the study (NCT00438451)
Timeframe: 58 weeks
| Intervention | days (Median) |
|---|---|
| Levetiracetam | NA |
| Carbamazepine | 265 |
| Lamotrigine | NA |
"The PNS is a 15-item scale. Each item can be scored from 1 to 9. There are a total score (includes all items, range:15 to 135) and two subscores: The cognitive toxicity subscore (10 items: Energy Level, Memory, Interest, Concentration, Forgetfulness, Sleepliness, Moodiness, Alertness, Attention Span, Motivation, range:10 to 90) and the somatomoto subscore (5 items: Vision, Walking, Coordination, Tremor, Speech, range:5-45). The score is calculated by taking the mean of all non-missing values times the number of items.~Lower values indicate better quality of life." (NCT00438451)
Timeframe: at week 58
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Cognitive toxicity subscore | Somatomotor subscore | Total Score | |
| Carbamazepine | 27.3 | 11.4 | 38.7 |
| Lamotrigine | 23.7 | 10.8 | 34.5 |
| Levetiracetam | 22.2 | 10.5 | 32.7 |
The QOLIE-31 is a 31 item score that measures the quality of life in epilepsy (each item with a range of 0 to 100). There are 7 sub-scores seizure worry (items 11,21,22,23,25), overall quality of life (items 1,14), emotional well-being (items 3,4,5,7,9), energy/fatigue (items 2,6,8,10), cognitive functioning (items 12,15,16,17,18,26), medication effects (items 24,29,30) and social functioning (13,19,20,27,28). These scores were combined to a total score by Total score = seizure worry*0.08 + overall quality of life*0.14 + emotional well-being*0.15 + energy/fatigue*0.12 + cognitive functioning*0.27 + medication effects*0.03 + social functioning*0.21 For all scores, higher values indicate better quality of life. Each score has a possible range from 0 to 100. (NCT00438451)
Timeframe: 58 weeks, final visit
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Seizure worry | Overall quality of life | Emotional well-being | Energy/fatigue | Cognitive functioning | Medication effects | Social functioning | Total Score | Health Scale | |
| Carbamazepine | 75.4 | 65.0 | 69.8 | 54.5 | 68.9 | 70.6 | 76.3 | 68.9 | 65.7 |
| Lamotrigine | 75.0 | 67.1 | 67.4 | 59.8 | 68.0 | 72.6 | 76.7 | 69.1 | 67.5 |
| Levetiracetam | 85.1 | 67.2 | 72.0 | 60.8 | 75.1 | 77.6 | 81.1 | 73.9 | 69.5 |
"Evaluation of current testing at V6:~≥29 score points: Inconspicuous; 26 to 28 score points: Borderline;~≤25 score points: Impaired" (NCT00438451)
Timeframe: 58 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| Without pathological findings | Borderline | Impaired | |
| Carbamazepine | 34 | 17 | 33 |
| Lamotrigine | 31 | 15 | 39 |
| Levetiracetam | 38 | 10 | 36 |
"Evaluation of Changes~Changes in the EpiTrack® Score were categorized as follows:~≥5 score points: Improved;~-3 to 4 score points: Unchanged;~≤-4 score points: Worsened" (NCT00438451)
Timeframe: week 58
| Intervention | participants (Number) | ||
|---|---|---|---|
| Improved | Unchanged | Worsened | |
| Carbamazepine | 16 | 56 | 8 |
| Lamotrigine | 15 | 53 | 13 |
| Levetiracetam | 15 | 61 | 6 |
29 reviews available for gabapentin and Abdominal Epilepsy
| Article | Year |
|---|---|
Gabapentin monotherapy for epilepsy: A review.
Topics: Anticonvulsants; Carbamazepine; Drug Resistant Epilepsy; Epilepsies, Partial; Epilepsy; Gabapentin; | 2023 |
Gabapentin add-on treatment for drug-resistant focal epilepsy.
Topics: Adult; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Drug Resistant Epilepsy; Drug Therapy, C | 2021 |
Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.
Topics: Adult; Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Epilepsies, Parti | 2017 |
Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.
Topics: Adult; Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Epilepsies, Parti | 2017 |
Gabapentin add-on treatment for drug-resistant focal epilepsy.
Topics: Adult; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Drug Resistant Epilepsy; Drug Therapy, C | 2018 |
Pregabalin add-on for drug-resistant focal epilepsy.
Topics: Anticonvulsants; Drug Resistant Epilepsy; Drug Therapy, Combination; Epilepsies, Partial; Gabapentin | 2019 |
Gabapentin add-on for drug-resistant partial epilepsy.
Topics: Adult; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Drug Resistance; Drug Therapy, C | 2013 |
Pregabalin versus gabapentin in partial epilepsy: a meta-analysis of dose-response relationships.
Topics: Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Epilepsies, | 2010 |
Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis.
Topics: Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsies, Partial; Fructose; Gabapentin; gam | 2011 |
Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.
Topics: Acetates; Adolescent; Adult; Age Factors; Amines; Antipsychotic Agents; Carbamazepine; Child; Clinic | 2004 |
Efficacy and tolerability of the new antiepileptic drugs, II: Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.
Topics: Acetates; Adolescent; Adult; Age Factors; Amines; Anticonvulsants; Carbamazepine; Child; Clinical Tr | 2004 |
Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epile
Topics: Acetates; Adult; Amines; Anticonvulsants; Carbamazepine; Child; Clinical Trials as Topic; Cyclohexan | 2004 |
Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery.
Topics: Amines; Amino Acid Sequence; Animals; Anticonvulsants; Calcium Channels; Cyclohexanecarboxylic Acids | 2007 |
[A novel antiepileptic, gabapentin (GABAPEN)].
Topics: Amines; Animals; Anticonvulsants; Brain; Calcium Channels; Clinical Trials, Phase III as Topic; Cycl | 2007 |
The new antiepileptic drugs.
Topics: Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Dioxolanes; Epilepsies, | 2007 |
New antiepileptic drugs for children: felbamate, gabapentin, lamotrigine, and vigabatrin.
Topics: Acetates; Adult; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Drug Approval; Epileps | 1994 |
Gabapentin: a new agent for the management of epilepsy.
Topics: Acetates; Adult; Age Factors; Amines; Anticonvulsants; Controlled Clinical Trials as Topic; Cyclohex | 1994 |
Clinical efficacy and safety of gabapentin.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Ep | 1994 |
Gabapentin: discussion.
Topics: Acetates; Amines; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Drugs, Inv | 1994 |
[Gabapentin (Neurontin): a new possibility in the add-on therapy of partial epilepsies].
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsies, Partial; Gabapentin; gam | 1996 |
Clinical efficacy of new antiepileptic drugs in refractory partial epilepsy: experience in the United States with three novel drugs.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Controlled Clinical Trials as Topic; Cyc | 1996 |
A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy.
Topics: Acetates; Amines; Anticonvulsants; Cost Control; Cyclohexanecarboxylic Acids; Epilepsies, Partial; G | 1996 |
Aggravation of focal epileptic seizures by antiepileptic drugs.
Topics: Acetates; Acute Disease; Adult; Amines; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 1998 |
Monotherapy trials with gabapentin for partial epilepsy.
Topics: Acetates; Ambulatory Care; Amines; Anticonvulsants; Carbamazepine; Controlled Clinical Trials as Top | 1999 |
Gabapentin in the management of convulsive disorders.
Topics: Acetates; Action Potentials; Amines; Animals; Anticonvulsants; Clinical Trials as Topic; Cyclohexane | 1999 |
Evidence-based medicine and antiepileptic drugs.
Topics: Acetates; Adult; Amines; Anticonvulsants; Confidence Intervals; Cyclohexanecarboxylic Acids; Drug Ad | 1999 |
Gabapentin for drug-resistant partial epilepsy.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsies, Partial; Gabapentin; gam | 2000 |
Gabapentin add-on for drug-resistant partial epilepsy.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Resistance; Drug Therapy, Combi | 2000 |
Drug treatment of benign focal epilepsies of childhood.
Topics: Acetates; Amines; Anticonvulsants; Child; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Dru | 2000 |
33 trials available for gabapentin and Abdominal Epilepsy
| Article | Year |
|---|---|
The efficacy of gabapentin in children of partial seizures and the blood levels.
Topics: Adolescent; Age Factors; Amines; Anticonvulsants; Child; Child, Preschool; Cyclohexanecarboxylic Aci | 2014 |
Adjunctive pregabalin vs gabapentin for focal seizures: Interpretation of comparative outcomes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Ac | 2016 |
Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial.
Topics: Adolescent; Adult; Aged; Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; | 2012 |
Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Asthenia; Clinical Protocols; Cyclohexan | 2002 |
Gabapentin and lamotrigine in Indian patients of partial epilepsy refractory to carbamazepine.
Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Ac | 2002 |
Serum concentrations and effects of gabapentin and vigabatrin: observations from a dose titration study.
Topics: Acetates; Amines; Anticonvulsants; Chromatography, High Pressure Liquid; Cyclohexanecarboxylic Acids | 2003 |
Treatment of partial seizures with gabapentin: double-blind, placebo-controlled, parallel-group study.
Topics: Adolescent; Adult; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relatio | 2006 |
The long-term safety and efficacy of gabapentin (Neurontin) as add-on therapy in drug-resistant partial epilepsy. The US Gabapentin Study Group.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Double-Blin | 1994 |
Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. The US Gabapentin Study Group No. 5.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Analysis of Variance; Anticonvulsants; Cyclohexanecarboxy | 1993 |
[Gabapentin (Neurontin): a new possibility in the add-on therapy of partial epilepsies].
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsies, Partial; Gabapentin; gam | 1996 |
[Clinical studies on gabapentin in Switzerland].
Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Child; Child, Preschool; Cyclohexanecarboxylic | 1996 |
Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Analysis of Variance; Anticonvulsants; Cognition Disorder | 1997 |
High dose gabapentin in refractory partial epilepsy: clinical observations in 50 patients.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Diarrhea; D | 1998 |
Conversion to high dose gabapentin monotherapy in patients with medically refractory partial epilepsy.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationship, D | 1998 |
Outcome evaluation of gabapentin as add-on therapy for partial seizures. "NEON" Study Investigators Group. Neurontin Evaluation of Outcomes in Neurological Practice.
Topics: Acetates; Adolescent; Adult; Aged; Aged, 80 and over; Amines; Anti-Anxiety Agents; Anticonvulsants; | 1998 |
A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77.
Topics: Acetates; Adolescent; Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Carbamazepine; Child; | 1998 |
Gabapentin in the treatment of refractory partial epilepsy in children with intellectual disability.
Topics: Acetates; Adolescent; Amines; Anticonvulsants; Child; Child, Preschool; Cyclohexanecarboxylic Acids; | 1998 |
A beneficial effect on mood in partial epilepsy patients treated with gabapentin.
Topics: Acetates; Adult; Affect; Aged; Amines; Anticonvulsants; Anxiety Disorders; Comorbidity; Cyclohexanec | 1999 |
Gabapentin as add-on therapy in children with refractory partial seizures: a 12-week, multicentre, double-blind, placebo-controlled study. Gabapentin Paediatric Study Group.
Topics: Acetates; Age Factors; Amines; Anticonvulsants; Child; Child, Preschool; Cyclohexanecarboxylic Acids | 1999 |
Monotherapy trials with gabapentin for partial epilepsy.
Topics: Acetates; Ambulatory Care; Amines; Anticonvulsants; Carbamazepine; Controlled Clinical Trials as Top | 1999 |
Gabapentin as adjunctive therapy for partial seizures.
Topics: Acetates; Adult; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dizziness; Dru | 1999 |
Dosing to efficacy with neurontin: the STEPS trial. Study of Titration to Effect Profile of Safety.
Topics: Acetates; Adult; Amines; Anticonvulsants; Clinical Trials, Phase III as Topic; Cyclohexanecarboxylic | 1999 |
Conversion from thrice daily to twice daily administration of gabapentin (GBP) in partial epilepsy: analysis of clinical efficacy and plasma levels.
Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Cross-Over Studies; Cyclohexanecarboxylic Acid | 2000 |
Efficacy of gabapentin as adjunctive therapy in a large, multicenter study. The Steps Study Group.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationship, D | 2000 |
Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomized, double-blind, dose titration study. GREAT Study Investigators Group. Gabapentin in Refractory Epilepsy Add-on Treatment.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Doub | 2000 |
Increased seizures after discontinuing carbamazepine: results from the gabapentin monotherapy trial.
Topics: Acetates; Adult; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dose-Response | 2000 |
Rapid initiation of gabapentin: a randomized, controlled trial.
Topics: Acetates; Adolescent; Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Child; Cyclohexanecar | 2001 |
Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin.
Topics: Acetates; Adult; Amines; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Dos | 2001 |
Efficacy and safety of gabapentin as an add-on therapy in refractory partial epileptic patients.
Topics: Acetates; Activities of Daily Living; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; D | 2001 |
Selected CSF biochemistry and gabapentin concentrations in the CSF and plasma in patients with partial seizures after a single oral dose of gabapentin.
Topics: Acetates; Administration, Oral; Adult; Amines; Anticonvulsants; Chromatography, High Pressure Liquid | 1992 |
Long-term treatment with gabapentin for partial epilepsy.
Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Double-Blind Meth | 1992 |
Gabapentin.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Respon | 1991 |
Gabapentin in partial epilepsy. UK Gabapentin Study Group.
Topics: Acetates; Adolescent; Adult; Amines; Analysis of Variance; Cyclohexanecarboxylic Acids; Double-Blind | 1990 |
27 other studies available for gabapentin and Abdominal Epilepsy
| Article | Year |
|---|---|
THROMBOCYTOPENIA WITH GABAPENTIN USAGE.
Topics: Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Drug | 2015 |
[New antiepileptic drugs].
Topics: Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsies, Partial; Epilepsy; | 2009 |
[Efficacy and tolerability of dose-escalation with generic gabapentin--a multicenter, non-interventional study].
Topics: Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Disorders of Excessive Somnolence; Dizz | 2011 |
What does the future hold for patients with epilepsy?
Topics: Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsies, Partial; Female; Fr | 2012 |
Costs, work absence, and adherence in patients with partial onset seizures prescribed gabapentin or pregabalin.
Topics: Adolescent; Adult; Aged; Amines; Anticonvulsants; Cohort Studies; Cyclohexanecarboxylic Acids; Datab | 2012 |
The 'number needed to treat' with levetiracetam (LEV): comparison with the other new antiepileptic drugs (AEDs).
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Clinical Trials as Topic; Cyclohexanecarboxylic Ac | 2002 |
Gabapentin increases the hyperpolarization-activated cation current Ih in rat CA1 pyramidal cells.
Topics: Acetates; Amines; Animals; Anticonvulsants; Cations; Cyclic AMP; Cyclohexanecarboxylic Acids; Dose-R | 2003 |
The use of lamotrigine, vigabatrin and gabapentin as add-on therapy in intractable epilepsy of childhood.
Topics: Amines; Anticonvulsants; Child; Child, Preschool; Cyclohexanecarboxylic Acids; Drug Therapy, Combina | 2005 |
Epilepsy in children: the evidence for new antiepileptic drugs.
Topics: Amines; Anticonvulsants; Carbamazepine; Child; Cross-Sectional Studies; Cyclohexanecarboxylic Acids; | 2005 |
Gabapentin for behavioral dyscontrol.
Topics: Acetates; Adolescent; Amines; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Cycloh | 1995 |
Gabapentin as add-on therapy for refractory partial epilepsy: results of five placebo-controlled trials.
Topics: Acetates; Amines; Anticonvulsants; Clinical Trials as Topic; Confidence Intervals; Cyclohexanecarbox | 1994 |
Gabapentin--a new anticonvulsant.
Topics: Acetates; Amines; Animals; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; D | 1994 |
Choreoathetotic movements: A possible side effect of gabapentin.
Topics: Acetates; Adult; Amines; Anticonvulsants; Athetosis; Chorea; Cyclohexanecarboxylic Acids; Dyskinesia | 1996 |
Efficacy of gabapentin therapy in children with refractory partial seizures.
Topics: Acetates; Adolescent; Amines; Anticonvulsants; Child; Child Behavior; Child, Preschool; Cyclohexanec | 1996 |
New antiepileptic drugs: case studies.
Topics: Acetates; Amines; Anticonvulsants; Child, Preschool; Cyclohexanecarboxylic Acids; Drug Resistance; E | 1997 |
Alopecia associated with gabapentin: first case.
Topics: Acetates; Adolescent; Alopecia; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsies, Pa | 1997 |
[Trials with gabapentin monotherapy in patients with complex partial or secondary generalized seizures].
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Do | 1997 |
Isolated ataxia as an idiosyncratic side-effect under gabapentin.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cerebellar Ataxia; Cyclohexanecarboxylic Acids; Dose-Respo | 1997 |
Gabapentin add-on therapy with adaptable dosages in 610 patients with partial epilepsy: an open, observational study. The French Gabapentin Collaborative Group.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Respon | 1998 |
A case of sustained massive gabapentin overdose without serious side effects.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cognition; Cyclohexanecarboxylic Acids; Drug Overdose; Epi | 1999 |
Gabapentin as add-on therapy in focal epilepsy: a computerized EEG study.
Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Brain; Brain Mapping; Cyclohexanecarboxylic Ac | 2000 |
Improved sexual function in three men taking lamotrigine for epilepsy.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsies, Partial; | 2000 |
Gabapentin-induced mood changes with hypomanic features in adults.
Topics: Acetates; Adult; Affect; Amines; Anticonvulsants; Chlamydia Infections; Cyclohexanecarboxylic Acids; | 2000 |
Oxcarbazepine in focal epilepsy and hepatic porphyria: a case report.
Topics: Acetates; Adult; Amines; Anticonvulsants; Carbamazepine; Comorbidity; Cyclohexanecarboxylic Acids; D | 2001 |
Management strategies for refractory localization-related seizures.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Administration Schedule; Drug T | 2001 |
AUStralian study of titration to effect profile of safety (AUS-STEPS): high-dose gabapentin (neurontin) in partial seizures.
Topics: Acetates; Adolescent; Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Australia; Cyclohexan | 2001 |
Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. 1993.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Double-Blind Method; Epilepsies, Par | 2001 |